Last updated on October 2017

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer


Brief description of study

Primary Objectives: To assess the antitumor activity (proportion of objective response by RECIST 1.1 criteria) of pembrolizumab with objective tumor response in patients with persistent, recurrent or metastatic endometrial cancer harboring an ultra-mutated or hyper-mutated (MMR gene-defective) phenotype identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP). To determine the nature and degree of toxicity of pembrolizumab as assessed by CTCAE in patients with persistent, recurrent or metastatic endometrial carcinoma. Secondary Objective(s): To estimate the duration of progression-free survival (PFS) and overall survival (OS).

Clinical Study Identifier: NCT02899793

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Alessandro D. Santin, M.D.

Yale New Haven Hospital
New Haven, CT United States
  Connect »